{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009846","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.598638+00:00","generated_at":"2026-05-16T10:59:13.106598+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Perspective Therapeutics provides VMT-α-NET and pipeline updates; 76% progression-free in NET trial","bullets":["VMT-α-NET Cohort 2: 19/25 pts (76%) progression-free at median ~13 wks additional follow-up vs ESMO 2025; 9/23 (39%) had RECIST response.","Safety in 56 pts: no DLTs, no treatment-related discontinuations; Grade 3+ AEs in 37.5%, one transient Grade 4 lymphopenia.","Cohort 3 (6.0 mCi) cleared by SMC after 8-patient DLT review; 9 patients treated as of Dec 31, 2025.","VMT01 melanoma: 9 patients dosed at 3.0 mCi (5 with nivolumab, 4 monotherapy) as of Dec 31; data submission planned after 24-week follow-up.","PSV359 FAP-targeting trial: 5 patients dosed across Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) with site activations underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009846","json":"https://secwatch.observer/filing/0001193125-26-009846.json","markdown":"https://secwatch.observer/filing/0001193125-26-009846.md","text":"https://secwatch.observer/filing/0001193125-26-009846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/0001193125-26-009846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/catx-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:59:13.106598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}